• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

Supply Agreement

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)
November 24, 2020
Pharmaceutical News

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib).

More
Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)
Pharmaceutical News

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETO™ (pralsetinib)

November 24, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies,

More
  • How To Overcome Common Breastfeeding Challenges
  • Can You Sue Your Doctor for Blindness Caused by Elmiron?
  • Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
  • FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop